Repligen (RGEN) Tops Q4 EPS by 21c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 7:30 AM ESTReports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growthOrganic revenue growth was 47% for the fourth quarter and 29% for the year 2020
WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2020, followed by our current financial guidance for the year 2021, and access information... More
